DaVita Clinical Research (DCR) is expanding its Central Laboratory services. The company’s test menu will increase by 43%, maintaining its position in advanced renal care as well as coverage in the areas of oncology, immunology, endocrinology, cardiology and anemia. DCR’s Central Lab is focused on providing clinical research in both complex/specialty populations and therapeutic areas, as well as chronic kidney disease (CKD) populations.  

The testing facility has added two new testing platforms, the Immulite 2000 XPi Immunoassay System and the AB Sciex QTrap 5500 LC/MS/MS system. Other additions include increased specimen management and storage capabilities for short- and long-term testing. The Central Lab facilities have also made continuous IT advancements for clean, timely data and customer access to lab results.

“We are proud of our recent investments in equipment and assay development,” stated DCR vice president of Commercial Development Kevin J. Goudreau. “These investments will allow us to supply central laboratory services outside of renal care. We will continue to invest heavily in assay development until the breadth of our offering covers virtually all therapeutic indications.”